Worldwide Illegal spread of GM crop !!

[Guest guest]

Jag -- has the wprld gone mad!!

 

All these people want to use THALIDOMIDE!!!

 

Thalidomide and Hematopoietic-Cell Transplantation for

Multiple Myeloma

Bart Barlogie, M.D., Ph.D., Guido Tricot, M.D., Ph.D.,

Elias Anaissie, M.D., John Shaughnessy, Ph.D., Erik

Rasmussen, M.S., Frits van Rhee, M.D., Ph.D.,

Athanasios Fassas, M.D., Maurizio Zangari, M.D., Klaus

Hollmig, M.D., Mauricio Pineda-Roman, M.D., Choon Lee,

M.D., Giampaolo Talamo, M.D., Raymond Thertulien,

M.D., Ph.D., Elias Kiwan, M.D., Somashekar Krishna,

M.D., Michele Fox, M.D., and John Crowley, Ph.D.

 

 

 

This Article

- Full Text

- PDF

- PDA Full Text

- PowerPoint Slide Set

- Supplementary Material

Translated Abstracts

Deutsch

Español

Français

Italiano

 

Tools and Services

- Add to Personal Archive

- Add to Citation Manager

- Notify a Friend

- E-mail When Cited

- E-mail When Letters Appear

 

More Information

- Find Similar Articles

- PubMed Citation

ABSTRACT

 

Background High-dose therapy with melphalan can

prolong survival among patients with multiple myeloma.

We assessed whether the addition of thalidomide, which

has activity against advanced and refractory myeloma,

would further improve survival.

 

Methods Between October 1998 and February 2004, 668

patients with newly diagnosed multiple myeloma

received two cycles of intensive melphalan-based

chemotherapy, each supported by autologous

hematopoietic stem-cell transplantation. A total of

323 were randomly assigned to receive thalidomide from

the outset until disease progression or undue adverse

effects, and 345 did not receive thalidomide. The

primary end point was the five-year event-free

survival rate. Secondary end points were complete

response and overall survival.

 

Results After a median follow-up of 42 months among

survivors, the thalidomide and control groups had

rates of complete response of 62 percent and 43

percent, respectively (P<0.001), and five-year

event-free survival rates of 56 percent and 44 percent

(P=0.01). The five-year rate of overall survival was

approximately 65 percent in both groups (P=0.90).

Median survival after relapse was 1.1 years in the

thalidomide group and 2.7 years in the control group

(P=0.001). Severe peripheral neuropathy and deep-vein

thrombosis occurred more frequently in the thalidomide

group than in the control group.

 

Conclusions When incorporated into high-dose therapy

for myeloma, thalidomide increased the frequency of

complete responses and extended event-free survival at

the expense of added adverse effects without improving

overall survival. (ClinicalTrials.gov number,

NCT00083551 [ClinicalTrials.gov] .)

 

 

Source Information

 

From the Myeloma Institute for Research and Therapy,

University of Arkansas for Medical Sciences, Little

Rock (B.B., G.T., E.A., J.S., F.R., A.F., M.Z., K.H.,

M.P.-R., C.L., G.T., R.T., E.K., S.K., M.F.); and

Cancer Research and Biostatistics, University of

Washington, Seattle (E.R., J.C.).

 

 

 

 

 

 

[Guest guest]

yes.. the world has gone mad..

what else do you want to know? sigh

 

-

james white

Thursday, March 09, 2006 8:13 AM

Re: Worldwide Illegal spread of GM crop !!

Jag -- has the wprld gone mad!! All these people want to use THALIDOMIDE!!!Thalidomide and Hematopoietic-Cell Transplantation forMultiple MyelomaBart Barlogie, M.D., Ph.D., Guido Tricot, M.D., Ph.D.,Elias Anaissie, M.D., John Shaughnessy, Ph.D., ErikRasmussen, M.S., Frits van Rhee, M.D., Ph.D.,Athanasios Fassas, M.D., Maurizio Zangari, M.D., KlausHollmig, M.D., Mauricio Pineda-Roman, M.D., Choon Lee,M.D., Giampaolo Talamo, M.D., Raymond Thertulien,M.D., Ph.D., Elias Kiwan, M.D., Somashekar Krishna,M.D., Michele Fox, M.D., and John Crowley, Ph.D. This Article- Full Text- PDF- PDA Full Text- PowerPoint Slide Set- Supplementary MaterialTranslated Abstracts Deutsch Español Français ItalianoTools and Services- Add to Personal Archive- Add to Citation Manager- Notify a Friend- E-mail When Cited- E-mail When Letters AppearMore Information- Find Similar Articles- PubMed CitationABSTRACTBackground High-dose therapy with melphalan canprolong survival among patients with multiple myeloma.We assessed whether the addition of thalidomide, whichhas activity against advanced and refractory myeloma,would further improve survival.Methods Between October 1998 and February 2004, 668patients with newly diagnosed multiple myelomareceived two cycles of intensive melphalan-basedchemotherapy, each supported by autologoushematopoietic stem-cell transplantation. A total of323 were randomly assigned to receive thalidomide fromthe outset until disease progression or undue adverseeffects, and 345 did not receive thalidomide. Theprimary end point was the five-year event-freesurvival rate. Secondary end points were completeresponse and overall survival.Results After a median follow-up of 42 months amongsurvivors, the thalidomide and control groups hadrates of complete response of 62 percent and 43percent, respectively (P<0.001), and five-yearevent-free survival rates of 56 percent and 44 percent(P=0.01). The five-year rate of overall survival wasapproximately 65 percent in both groups (P=0.90).Median survival after relapse was 1.1 years in thethalidomide group and 2.7 years in the control group(P=0.001). Severe peripheral neuropathy and deep-veinthrombosis occurred more frequently in the thalidomidegroup than in the control group.Conclusions When incorporated into high-dose therapyfor myeloma, thalidomide increased the frequency ofcomplete responses and extended event-free survival atthe expense of added adverse effects without improvingoverall survival. (ClinicalTrials.gov number,NCT00083551 [ClinicalTrials.gov] .)Source InformationFrom the Myeloma Institute for Research and Therapy,University of Arkansas for Medical Sciences, LittleRock (B.B., G.T., E.A., J.S., F.R., A.F., M.Z., K.H.,M.P.-R., C.L., G.T., R.T., E.K., S.K., M.F.); andCancer Research and Biostatistics, University ofWashington, Seattle (E.R., J.C.).